Osimertinib
VIDEO: ADAURA trial ‘paradigm-shifting’ for lung cancer precision medicine
VIDEO: ASCO Plenary gives new data on adjuvant osimertinib
VIDEO: ASCO 2020 ‘incredibly exciting’ for lung cancer data
Adjuvant osimertinib extends DFS in EGFR-mutated NSCLC
Adjuvant osimertinib shows ‘overwhelming efficacy’ for EGFR-mutated lung cancer
Osimertinib improves OS in untreated, advanced NSCLC
First-line osimertinib improved OS compared with standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors among patients with previously untreated advanced EGFR-mutated non-small cell lung cancer, according to results from the randomized phase 3 FLAURA trial presented at European Society for Medical Oncology Asia Congress and simultaneously published in The New England Journal of Medicine.
10 important updates for Lung Cancer Awareness Month
Front-line osimertinib improves OS in EGFR-mutated lung cancer
BARCELONA, Spain — Osimertinib significantly extended OS compared with standard epidermal growth factor receptor tyrosine kinase inhibitors as front-line treatment for EGFR-mutated advanced non-small cell lung cancer, according to late-breaking results of the randomized phase 3 FLAURA study presented at European Society for Medical Oncology Congress.